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Background: TREFAMS is an acronym for TReating FAtigue in Multiple Sclerosis, while ACE refers to the
rehabilitation treatment methods under study, that is, Aerobic training, Cognitive behavioural therapy, and Energy
conservation management. The TREFAMS-ACE research programme consists of four studies and has two main
objectives: (1) to assess the effectiveness of three different rehabilitation treatment strategies in reducing fatigue
and improving societal participation in patients with MS; and (2) to study the neurobiological mechanisms of action
that underlie treatment effects and MS-related fatigue in general.
Methods/Design: Ambulatory patients (n = 270) suffering from MS-related fatigue will be recruited to three
single-blinded randomised clinical trials (RCTs). In each RCT, 90 patients will be randomly allocated to the
trial-specific intervention or to a low-intensity intervention that is the same for all RCTs. This low-intensity
intervention consists of three individual consultations with a specialised MS-nurse. The trial-specific interventions
are Aerobic Training, Cognitive Behavioural Therapy, and Energy Conservation Management. These interventions
consist of 12 individual therapist-supervised sessions with additional intervention-specific home exercises. The
therapy period lasts 16 weeks. All RCTs have the same design and the same primary outcome measures:
fatigue - measured with the Checklist Individual Strength, and participation - measured with the Impact on
Participation and Autonomy questionnaire. Outcomes will be assessed 1 week prior to, and at 0, 8, 16, 26 and 52
weeks after randomisation. The assessors will be blinded to allocation. Pro- and anti-inflammatory cytokines in
serum, salivary cortisol, physical fitness, physical activity, coping, self-efficacy, illness cognitions and other
determinants will be longitudinally measured in order to study the neurobiological mechanisms of action.
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Discussion: The TREFAMS-ACE programme is unique in its aim to assess the effectiveness of three rehabilitation
treatments. The programme will provide important insights regarding the most effective treatment for MS-related
fatigue and the mechanisms that underlie treatment response. A major strength of the programme is that the
design involves three almost identical RCTs, enabling a close comparison of the treatment strategies and a strong
overall meta-analysis. The results will also support clinical practice guidelines for the treatment of MS-related
fatigue.
Trial registrations: Current Controlled Trials ISRCTN69520623, ISRCTN58583714, and ISRCTN82353628
Keywords: Multiple sclerosis, Fatigue, Aerobic training, Energy conservation management, Cognitive behavioural
therapy, Biomarkers, HPA-axis, Cortisol, Cytokines, Rehabilitation medicine, Randomised controlled trialBackground
Multiple sclerosis (MS) is a neurodegenerative disease
characterised by demyelinisation, axonal loss and inflam-
mation of the central nervous system (CNS). Although
the first description of MS dates back to the mid-19th
century, in spite of this long history the aetiology is still
unknown and no curative treatment is available [1]. The
disease is most probably caused by an interplay between
immunological, environmental and genetic factors [2,3].
MS affects young and middle-aged people, with women
twice as likely to be affected as men, and is known to
cause a variety of clinical symptoms such as neurological
impairments, fatigue, depression and pain [2].
Fatigue is one of the most often reported and disabling
symptoms in MS and restricts societal participation and
performance in daily life at home, at work and in leisure
activities [4-6]. Although the importance of fatigue as a
disabling symptom of MS is widely acknowledged, there
is no consensus on the definition of fatigue. DeLuca [7]
defines fatigue as the reduction in performance with ei-
ther prolonged or unusual exertion. Furthermore, fatigue
can be sensory, motor, cognitive or subjective. The Mul-
tiple Sclerosis Council for Clinical Practice Guidelines
[8] defines fatigue in MS as a subjective lack of physical
and/or mental energy that is perceived by the individual
(or caregiver) to interfere with usual and desired activ-
ities. Chaudhuri and Behan [9] distinguish central fatigue
from peripheral fatigue, and define central fatigue as the
failure to initiate and/or sustain attentional tasks (mental
or cognitive fatigue) and physical activities (physical fa-
tigue). Peripheral fatigue is described as muscle fatigability
due to disorders of muscle and neuromuscular junctions.
The definitions of DeLuca [7], the MS Council for Clinical
Practice Guidelines [8] and the concept of central fatigue
outlined by Chaudhuri and Behan [9] concur with our
view that MS-related fatigue is a multifaceted symptom.
Fatigue in MS can also be subdivided into primary and
secondary. Primary fatigue relates to specific pathophysio-
logical mechanisms that are the direct consequence of the
MS disease process. On the other hand, a number of fac-
tors, while not considered primary causes of MS-relatedfatigue, may be secondary contributors. These factors are
not unique to MS, but are the result of symptoms of MS
such as sleep problems due to spasm or urinary problems,
depression or physical deconditioning. Fatigue might also
be a side effect of disease modifying drugs.
Although the exact pathophysiological mechanism be-
hind MS-related fatigue is unknown, it is most likely multi-
factorial. A number of pathophysiological mechanisms have
been proposed including dysregulation of the immune sys-
tem, dysfunction of the CNS, impaired nerve conduction,
neuro-endocrine/neurotransmitter dysregulation, the in-
volvement of the autonomic nervous system and energy de-
pletion [10,11]. Available information can be combined in a
biological model in which environmental stressors such as
infections, immunisation, trauma and life events influence
genetically predisposed variables such as the sensitivity of
the hypothalamic-pituitary-adrenal axis (HPA-axis), gluco-
corticoid receptors and the noradrenaline system [9,12,13].
Consequently, fatigue is triggered in susceptible individuals.
In addition to disease-related, genetic and environmental
factors, psychological mechanisms may play an important
role in causing and sustaining MS-related fatigue [12-14].
In clinical practice, MS-related fatigue is often treated
with a combination of therapies, which makes it difficult to
distinguish the effect of each therapy component. Due to
the limitations of available evidence, current pharmaco-
logical approaches to treating MS-related fatigue are mainly
based on preliminary studies and expert consensus. Aman-
tadine, Modafinil and Aminopyridine are pharmacological
strategies mainly used by neurologists [15]. Current evi-
dence supporting the effectiveness of non-pharmacological
interventions such as Aerobic Training (AT) [16-22], Cog-
nitive Behavioural Therapy (CBT) [23] and Energy Conser-
vation Management (ECM) [24-26] on MS-related fatigue
is encouraging, but findings are heterogeneous and only a
few studies have evaluated MS-related fatigue as the pri-
mary outcome measure [27]. Moreover, the methodological
quality of non-pharmacological trials is often hampered by
issues such as the complexity of the (multidisciplinary)
treatment, the lack of adequate control groups, treatment
blinding of patients and assessors, and the expertise of the
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sion of the CONSORT statement for non-pharmacological
trials [28]. Systematic reviews of exercise therapy and en-
ergy conservation management trials are underway or re-
cently published [29,30].
TREFAMS is an acronym for the TReating FAtigue in
MS programme, and ACE refers to the rehabilitation
treatment methods under study, that is, Aerobic training,
Cognitive behavioural therapy, and Energy conservation
management. The programme has two main objectives:
(1) to assess the effectiveness of three different rehabilita-
tion treatment strategies in reducing fatigue and in im-
proving societal participation in individual MS patients;
and (2) to study the biological mechanisms that underlie
treatment effects and MS-related fatigue in general. The
TREFAMS-ACE research programme includes three ran-
domised clinical trials (RCTs), and one explanatory study
on the biological mechanisms of action that underlie treat-
ment effects and MS-related fatigue in general.
A significant body of evidence now implicates both
HPA-axis abnormalities and immune markers in the
pathophysiology of MS-related fatigue. MS patients with
fatigue exhibited a higher activity of the HPA-axis than pa-
tients without fatigue [13,31]. Earlier studies have exam-
ined a possible relationship between cytokines and fatigue
in MS [32,33]. A study of pro-inflammatory (IFN-γ, TNF-α)
and anti-inflammatory (IL-10) cytokine production in MS
patients showed that patients with fatigue had a signifi-
cantly higher production of IFN-γ and TNF-α than patients
without fatigue. IL-10 production did not significantly differ
between the two groups [32]. Flachenecker and Bihler [33]
found a relationship between TNF-α mRNA expression
and fatigue, but not between fatigue and IFN-γ or IL-10. In
view of a relationship to inflammatory markers found in
two independent studies and the higher HPA-axis reactivity
in MS, we hypothesise that fatigue in patients with MS is
stress-related and that it is caused by an inflammatory
mechanism. In addition, we assume that the extent of im-
balance between pro-inflammatory and anti-inflammatory
cytokines is associated with the severity of fatigue.
AT is aimed at improving physical fitness and at redu-
cing an inactive, deconditioning lifestyle. Improved phys-
ical fitness may lead to normalisation of HPA-axis
functioning [34], a reduction in pro-inflammatory cyto-
kines and/or an increase in anti-inflammatory cytokines
[35], leading to a reduction in MS-related fatigue. We hy-
pothesise that an improved physical fitness due to AT will
be accompanied by reduced fatigue and, as a consequence,
improved societal participation.
CBT focuses on fatigue-maintaining cognitions and
behaviour, examples of which are insufficient coping
with MS or MS-related fatigue, fear of disease progres-
sion, dysregulation of activity or sleep, low social support
and focusing on fatigue. The general aim of CBT is toimprove daily functioning and to decrease fatigue by chan-
ging fatigue-maintaining cognitions and behaviour, within
the limits of the MS [36]. We hypothesise that CBT may
reduce perceived stressors (for example, environmental,
psychological and biological), and consequently may lead
to normalisation of HPA-axis functioning and cytokine
profiles.
ECM includes energy conservation strategies, ergo-
nomic advice and coaching aimed at more efficient use of
available energy. Energy conservation strategies have been
defined as the identification and development of activity
modifications to reduce fatigue through a systematic ana-
lysis of daily work, home and leisure activities in all rele-
vant environments [8]. Packer et al. [37] were the first to
develop an ECM treatment protocol for a 6-week group
course. In a clinical trial, this group course proved to be
effective in patients with MS, both immediately following
the course and after 1 year [24,25]. The treatment goal of
ECM is to promote a positive attitude aimed at stimulat-
ing active decision-making and the optimal use of avail-
able energy in relation to the unique needs of each
individual. We hypothesise that ECM may lead to a reduc-
tion in environmental and psychological stressors and
consequently to the normalisation of biological stressors
(HPA-axis functioning, cytokines), which may in turn lead
to reduced fatigue and improved participation.
Accordingly, the following research questions have
been formulated in the TREFAMS-ACE programme:
1. What is the effectiveness of Aerobic Training on
fatigue and participation? Can this effect be
attributed to an increase in fitness parameters?
2. What is the effectiveness of CBT on participation
and fatigue? Can this effect be explained by altered
cognitions regarding fatigue?
3. What is the effectiveness of Energy Conservation
Management advice on fatigue and participation?
Can this effect be attributed to the implementation
of ergonomic advice or adherence to altered time-
schedules?
4. Which treatment strategy reduces fatigue and
improves participation most effectively?
5. Does effective therapy lead to normalisation of HPA-
axis function, a reduction in pro-inflammatory
cytokines or an increase in anti-inflammatory
cytokines?
Methods/Design
Design
TREFAMS-ACE is a multicentre programme that in-
cludes three single-blinded RCTs with repeated mea-
surements in time, in which the effectiveness of Aerobic
Training, CBT and Energy Conservation Management
on MS-related fatigue and participation in patients with
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parallel-arms design (Figure 1), the only difference being
the specific intervention applied [28]. Patients will be
randomised to receive either a high-intensity trial-specific
treatment, which consists of a series of 12 therapist-led
sessions in 4 months, or a low-intensity treatment by an
experienced MS-nurse, which consists of three consulta-
tions in 4 months. Participants will be followed for 1 year.
In addition to the three clinical trials, a fourth study
has been defined that will focus on biological outcome
measurement and understanding the biological mecha-
nisms of action underlying MS-related fatigue [38,39].
This study should also help to improve our understand-
ing of the biological mechanisms of the four interven-
tions under study (see Figure 1).
The medical ethics committee of the VU University Med-
ical Center approved the TREFAMS-ACE programme.
Additionally, local feasibility statements were obtained from
each participating medical centre.
Participants
The 270 adult patients (90 patients per RCT, and 45 per
intervention group) required will have to fulfill the follow-
ing inclusion criteria:(a) definitive diagnosis of MS; (b) se-
verely fatigued; (c) ambulatory patients; (d) no evident
signs of an exacerbation, or a corticosteroid treatment in
the past 3 months; (e) no current infections; (f:) no an-
aemia; (g) a normal thyroid function. The exclusion cri-
teria are: (a) depression; (b) primary sleep disorders; (c)
severe co-morbidity; (d) current pregnancy or having
given birth in the past 3 months; (e) pharmacologicalFigure 1 The design of the TREFAMS-ACE programme.treatment for fatigue that was started in the past 3 months
(for example, Amantadine, Modafinil, Ritalin, Pemoline); (f)
non-pharmacological therapies for fatigue that took place
in the past 3 months. See Table 1 for the operationalisation
of the inclusion and exclusion criteria.
Recruitment strategy
To avoid contamination of interventions, each RCT will
be carried out at a different (university) medical centre:
the AT study will be conducted in the St Antonius Hos-
pital, Nieuwegein, in collaboration with the University
Medical Center Utrecht, the CBT study will be conducted
at the VU University Medical Center in Amsterdam and
at the University Medical Centre Nijmegen (UMCN),
and the ECM study will be conducted at the Erasmus
MC-University Medical Center, Rotterdam, and Re-
habilitation Center Leijpark in Tilburg. Patients will ini-
tially be recruited through the participating main study
centres. The Dutch patient organisation Multiple Scler-
osis Vereniging Nederland (MSVN) has been involved
since the design phase of the research programme, and
has offered to help with recruitment. If the main study
centres are not able to recruit sufficient participants, re-
cruitment will also take place in hospitals and rehabili-
tation centres in the neighbourhood of the main study
centres. MS-nurses, neurologists and residents in neur-
ology and rehabilitation medicine will inform poten-
tially eligible patients about the TREFAMS-ACE study.
A neurologist or a rehabilitation physician will check
the inclusion and exclusion criteria listed in Table 1 in
the case of a potentially eligible patient. Subsequently,
Table 1 Inclusion and exclusion criteria TREFAMS-ACE trials
Inclusion criteria Exclusion criteria
Definitive diagnosis of MS Depression (HADS depression >11)
Severely fatigued (CIS20r-fatigue ≥35) Primary sleep disorders
Aged between 18 and 70 years Severe co-morbidity (CIRS item scores ≥3)
Ambulatory patients (an EDSS score ≤6) Current pregnancy or having given birth in the past 3 months
No evident signs of an exacerbation or a corticosteroid treatment in the past 3 months Pharmacological treatment for fatigue in the past 3 months
No infections (normal leukocytes and C-reactive protein in blood) Non-pharmacological therapies for fatigue in the past 3 months
No anaemia (normal haemoglobin and haematocrit in blood)
No thyroid dysfunction (normal thyroid stimulating hormone (TSH) in blood)
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complete an informed consent form before participating
in the study.
Interventions
Aerobic training (AT)
AT aims to improve the participant’s fitness and consists
of 12 physiotherapist-led exercise sessions on a bicycle
ergometer (Table 2). Moreover, participants will be pro-
vided with an identical bicycle ergometer at home on
which they will be asked to perform additional training
sessions, leading to the recommended three sessions per
week. Each 30-min interval-type training session consists
of six cycles of 5 min. Each cycle consists of 3 min of
low intensity exercise, 1 min of moderate intensity exer-
cise and 1 min of high intensity exercise. At the start of
the treatment and after 8 weeks of training, current fit-
ness levels will be assessed with a graded maximal exer-
cise test to volitional exhaustion. Following the 8-week
maximal exercise test, exercise intensities will be ad-
justed to meet the newly obtained fitness level. After
completion of the supervised training programme, pa-
tients will be encouraged to continue exercising and to
remain physically active. Generally, physiological adapta-
tions to aerobic training occur when: (1) the training in-
tensity is at least 60% VO2max, and (2) the training isTable 2 AT programme
45-min session of bicycle
ergometer training
Details
Warming-up • 5 min at 25% to 40% Wmax
Aerobic training • Six cycles of 5 min: 3 min 40% Wm
• Cadence: 60-80 revolutions per min
• Heart rate should not exceed 80% o
• Training intensity will be updated o
• The work rate can be adjusted, base
Cooling down 10 min
• All training sessions and adjustmen
Home exercises Participants will be provided with an
training sessions, leading to the recocarried out at least three times a week [40]. The current
treatment protocol addresses both factors.
Cognitive behavioural therapy (CBT)
CBT is directed at behaviours or cognitions that perpetu-
ate fatigue. Examples are dysfunctional cognitions with re-
spect to MS, fatigue or pain, persistent focusing on
symptoms, deregulation of physical and social activities
and a lack of social support [41,42]. It is thought that fa-
tigue will decrease if these perpetuating factors are identi-
fied by the patient him/herself and changed. CBT consists
of 12 sessions over a 4-month period. Ten different mod-
ules have been developed to target specific fatigue
maintaining factors [43] (Table 3). CBT will be customised
to each individual patient using indicator criteria for each
module that are based on cutoff scores on questionnaires
and on a diagnostic interview (Table 3). In the final ther-
apy sessions, special attention will be paid to integrating
the skills obtained into daily life and how to handle behav-
ioural relapses. The effectiveness of this theory-based CBT
strategy has already been investigated in several other pa-
tient populations and healthcare settings [44-48].
Energy conservation management (ECM)
The ECM treatment protocol is based on a group course
for energy conservation developed by Packer et al. [37].ax, 1 min 60% Wmax and 1 min 80% Wmax
(rpm)
f the predicted maximal heart rate
nce during the training, according to the 8-week maximal exercise test
d on the clinical expertise of the supervising physiotherapist
ts to the work rate are recorded in the training log
identical bicycle ergometer at home so that they can perform additional
mmended three sessions per week
Table 3 CBT modules
Module Questionnaires and instruments
1. Formulating goals For all participants
This module applies to all participants. Concrete and obtainable treatment goals are formulated during therapy.
Goals comprise activities that the participant wishes to do when the fatigue has decreased or disappeared.
2. Sleep/wake rhythm SIP sleep and rest ≥60 [49]
The importance of a regular sleep/wake rhythm and good sleep hygiene is explained
to the patient. Furthermore, the sleep/wake rhythm of will be discussed and
suggestions for improvement given.
3. Beliefs regarding MS Impact of Event Scale (IES) ≥20 [50]
Participants will receive realistic information about MS. Dysfunctional cognitions about MS or
the future are identified and challenged, and the participant is supported in forming more
functional cognitions. Problems regarding acceptance of the disease are also addressed.
Pictorial Representation of Illness Measure
(PRISM): Burden of MS heavier than burden
of fatigue [51]
Illness Cognition Questionnaire (ICQ),
concentration ≤12 [52]
Cognitive Behavioural Responses to
Symptoms Questionnaire (CBRSQ) [53,54]:
Resting behaviour >14,3;
All-or-nothing behaviour >12.9;
Symptom focusing >15.5;
Catastrophising >12.6;
Embarrassment >16.4;
Damage >20.5;
Fear avoidance >15.3
HADS [55]
Depression >9
Anxiety >9
Fear of disease Progression Questionnaire
(FoP-Q), ≥4 on at least 75% of the 34
Anxiety items [56,57]
4. Beliefs regarding fatigue SES-28 fatigue ≤19
Participants are supported in changing dysfunctional views about fatigue such
as a lack of self-efficacy, catastrophising fatigue and somatic attributions.
Jacobsen Fatigue Catastrophising
Scale ≥16 [58,59]
5. Focusing on fatigue Illness Management Questionnaire (IMQ),
focusing on symptoms ≥4 [60]
The concept of persistent focusing on fatigue and its consequences are discussed.
Participants practise redirecting their attention from fatigue to activities and
other sensations. Talking about fatigue is discouraged.
6. Regulation of physical activity Activity Interview and Activity Monitor
Depending on their level of activity, participants learn how to divide their activities,
followed by a systematic increase in regular physical activity to obtain predefined goals.
7. Regulation of social activity SIP social interaction ≥100 [49]
Patients are empowered to expand social activities and deal with problems that
can arise during social interaction.
SF36 social functioning ≤65 [61]
8. Regulation of mental activity CIS20r concentration ≥18 [62]
Participants are supported with regards to practising and expanding mental activities such as
working on the computer or reading. Participants learn how to deal with possible cognitive
deficits such as concentration or memory problems.
9. Role of the environment Social Support List (SSL) [63]
Unrealistic expectations of the environment are addressed and more realistic expectations are
promoted. Participants learn how to express their limits and boundaries to ‘significant others’.
Discrepancies ≥50;
Negative interactions ≥14
10. Handling pain SF36 bodily pain ≤60 [61]
Dysfunctional cognitions about pain are challenged and replaced by more functional cognitions. Pain Catastrophising Scale (PCS) ≥16 [64]
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Table 4 Individual energy conservation management
Sessions Content of the sessions
Introduction
session
• Getting to know the patient, identification of
problems in daily life with help of the COPM,
impact of fatigue on daily life
• Hand out workbook IECM, activity list per day/week to
give insight in load and loadability of the patient, and
learning style assessment
Analysis of the
problems
• Discuss activity/participation problems, outcomes
of load and loadability from the activity lists
• Analysis of problems, determine questions of help,
and the learning and approaching style
• Formulate the problems and treatment goals
Treatment
sessions
a. Information about fatigue
• types, causes and factors influencing fatigue
• banking (saving) and budgeting (deciding how to
spend) energy
b. Importance of rest
• how fatigue can influence your daily life
• rest as a way of relieving fatigue
c. Balancing your schedule
• components of a balanced lifestyle
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ment (IECM), is individualised and consists of 12 45-min
sessions over 4 months, given by a trained occupational
therapist. For the IECM, the original content of the Packer
et al. group programme will be divided up to fit the 4-
month treatment period. Attention will also be paid to in-
dividual learning and approaching styles to assimilate the
programme contents. Motivational interviewing will be
used as a communication technique to assist patients in
exploring and resolving ambivalence to change. Table 4
shows the content of the IECM. A variety of teaching
methods will be used, including providing information,
discussions, long-term and short-term goal setting, prac-
tice activities and homework activities, to assist the pa-
tient’s integration of energy conservation principles into
the performance of everyday tasks. The aim of ECM is not
so much to correct the underlying mechanisms of fatigue,
nor to accept that the solution is to decrease activity levels
or reduce the breadth and extent of activities. Instead, the
aim is to promote a positive attitude aimed at active
decision-making and the optimum use of the available en-
ergy to fit the unique needs of each individual. ECM is
also intended to reduce the impact and severity of fatigue,
to increase patients’ use of energy-conserving strategies
and to improve their confidence in their ability to manage
fatigue [37].• how to balance (light and heavy) activities
• planning a weekly schedule
d. Communication
• expressing needs to others
• breaking down negative attitudes about fatigue
and rest
e. Priorities and standards
• breaking down activities in order to simplify them
as much as possible
• budgeting energy, making decisions about
priorities and standards
f. How to do activities
g. Ergonomics, body positions and assistive devices
• organisation of needed environments (work,
home) to promote good body mechanics
• Organisation of needed environments to save
energy
• Technology and equipment that can save energy
• Structure of body/biomechanics
• How to use body properly/ergonomics
Evaluation sessionMS-nurse consultations
The low-intensity treatment by experienced MS-nurses
consists of three consultations of 45 min over a 4-month
period. The content of the consultations led by the MS-
nurse will cover two important aspects to control for: (1)
reliable information on MS-related fatigue; and (2) atten-
tion from an experienced MS professional in order to re-
assure the patient that his/her concerns or questions will
be taken seriously [65]. In the first consultation, the pa-
tient receives a booklet containing general information
about MS-related fatigue and factors that may influence
fatigue. This booklet was designed by the TREFAMS-ACE
research team to provide patients with standardised infor-
mation about fatigue, without adding details regarding
specific interventions so as to avoid overlap with the trial-
specific interventions. In the remaining two consultations,
participants will have the opportunity to discuss their per-
sonal experiences in coping with fatigue, ask questions
about the booklet and discuss other fatigue-related issues.
The consultations with the MS-nurses should not be con-
sidered as ‘usual care’ because, due to the TREFAMS-ACE
study design, the MS-nurses are restricted in referring pa-
tients to a psychologist, physiotherapist or other healthcare
professional within the hospital. In the Netherlands, timely
referral is an important aspect of normal MS-nursing
practice.Therapist training
All involved therapists were selected based on their ex-
perience with the intervention and with treating MS pa-
tients. Furthermore, all received training that was focused
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TREFAMS-ACE study.
Physiotherapists experienced in cardio-respiratory train-
ing were introduced to the exercise protocol, the use of
the bicycle ergometer, study materials and measurements
in TREFAMS-AT.
The psychologists involved in the TREFAMS-CBT study
all received an additional 4-day CBT training course at the
Expert Centre Chronic Fatigue of UMCN. The training
course consisted of an introduction to the protocol, train-
ing in the content of each treatment module and how to
determine which modules are indicated for a specific par-
ticipant. The skills needed to change patient cognition and
behaviours were practised during role-playing, with the
help of simulated patients. To ensure the quality of the
CBT, weekly peer conversations between therapists, in
which experiences with the TREFAMS-CBT participants
will be shared, are part of the therapist training.
Occupational therapists already familiar with energy
conservation strategies and the Packer group course ‘Man-
aging Fatigue’ received a 1-day training course in the
implementation of the individual Energy Management
Course (IECM). This course was given by the researcher,
together with an expert therapist in energy conservation
management. Training consisted of a thorough explanation
of the content of the 12 sessions and how sessions can be
individually tailored. In addition, occupational therapists
not yet qualified in applying Motivational Interviewing had
to attend a 3-day Motivational Interviewing course.
All MS-nurses involved in one of the RCTs partici-
pated in a 1-day training course. In this course the MS-
nurses shared their approach to taking a fatigue-related
nursing history, they were instructed as to how to pro-
vide relevant information on MS-related fatigue without
giving concrete therapeutic advice, and they were in-
formed of the restrictions concerning the referral of pa-
tients to other healthcare professionals within the
hospital (MS team members). These newly-learned skills
were practised using role-playing.Outcome measures
Outcome measures consist of validated self-reported ques-
tionnaires, blood and saliva, activity monitoring and phys-
ical fitness tests. All primary and secondary outcomes will
be assessed 1 week prior to, and at 0, 8, 16, 26 and 52
weeks after randomisation. The self-reported question-
naires will be offered to patients via the internet or on
paper, and will be completed at home. Within each self-
reported questionnaire, the sequence of questions will be
randomised between measurement occasions. The draw-
ing of blood samples (according to the study protocol),
physical fitness tests and assessor-based interviews will
take place at the outpatient clinic of the participatingcentres. Saliva sampling will take place at home and in-
cludes several time-points per day.
Primary outcome measures
1. Fatigue will be measured with the Checklist Individual
Strength (CIS20r), domain fatigue [62,66]. This multidi-
mensional questionnaire consists of 20 items, divided
into four dimensions of fatigue and related behavioural
aspects, including: (a) the subjective experience of fa-
tigue (8 items); (b) reduction in motivation (4 items); (c)
reduction of physical activity (3 items); and (d) reduction
in concentration (5 items). The CIS20r focuses on fa-
tigue in the past 2 weeks. Each item is answered using a
7-point scale. The CIS20r fatigue score is a sum score
that can vary between 8 and 56 points. Recently, the re-
producibility, distribution-based responsiveness and con-
current validity of the CIS20r were investigated in
patients with MS [67]. Despite good test-retest reliability,
a smallest detectable change of 11.8 points was found,
leading to the recommendation to monitor trial partici-
pants repeatedly over time using a set of complementary
fatigue scales [67]. A systematic review of the measure-
ment properties of 31 fatigue questionnaires confirms
this recommendation [68].
2. Societal participation will be assessed with the Im-
pact on Participation and Autonomy questionnaire (IPA)
[69]. The IPA questionnaire was developed to assess the
severity of restrictions in participation and individual
needs related to participation and autonomy. The IPA is
a generic questionnaire that addresses: (a) perceived par-
ticipation, reflected in 31 items in five domains, that is,
autonomy indoors, autonomy outdoors, family role, so-
cial relations, work and education; and (b) the experi-
ence of problems related to every aspect of participation,
reflected in eight problem experience scores [69]. An
anchor-based responsiveness study in a heterogeneous
outpatient rehabilitation population showed that the IPA
was moderately able to detect within-patient improve-
ment over time [69]. No studies on the responsiveness
and minimal important change of the IPA in patients
with MS are yet available [70].
Secondary outcome measures
MS-related fatigue is a multifaceted symptom with vari-
ous types of expression. Therefore, several other fatigue
measures are also included. The impact of fatigue will be
measured with the Modified Fatigue Impact Scale
(MFIS) and the Fatigue Severity Scale (FSS) [71,72]. The
MFIS assesses the effects of fatigue in terms of physical,
cognitive and psychosocial functioning. The FSS evalu-
ates the severity and impact of fatigue in patients with
MS. A patient-reported diurnal course of fatigue during
1 day will be assessed using short message services
(SMS) technology. Moreover, the Rehabilitation Activities
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Form 36 (SF36) will be used to measure daily functioning
and participation [61,73].
Determinants
These include descriptive variables, mediators (that is,
intervening causal variables), confounding or effect-
modifying factors that have been shown to be related to
the interventions, and fatigue and participation in MS
patients [53,74]. In multifactorial, complex situations
such variables can act in different ways in different situa-
tions or different analyses and will therefore be further
specified in forthcoming articles.
Demographic and disease characteristics
Demographic information includes age, gender, ethni-
city, living situation, level of education, work and in-
come. The disease-related variables that will be assessed
include the type of MS, neurological symptoms, the
Expanded Disability Status Scale (EDSS), the number of
exacerbations in the year prior to inclusion, the use of
disease modifying drugs and other medication, co-
morbidities and healthcare use. The EDSS and the Cu-
mulative Illness Rating Scale (CIRS) will be assessed by a
physician at baseline and after 52 weeks [75-77]. Cogni-
tive deficits will be assessed at baseline by the Mini
Mental State Examination [78].
Physical activity and physical fitness
The amount of physical activity and frequency of move-
ment will be registered by means of a tri-axial activity
monitor (ActiGraph GT3X+) that will be worn for 7 days.
The Physical Activity Scale for Individuals with Physical
Disabilities (PASIPD) is a self-reported questionnaire that
assesses physical activity over the preceding 7 days. The
PASIPD assesses physical activity in three domains: recre-
ation, household and occupation activities [79,80].
In a subgroup of participants, cardio-respiratory fitness
will be assessed by means of a maximum capacity test
(VO2max test). Participants will perform this test on an
electromagnetic bicycle ergometer. Work rate will be pro-
gressively increased by 25 + 10 W/min (women) or 25 +
15 W/min (men) until volitional exhaustion, rpm <45 or
for safety reasons. In addition, patients will walk as far as
possible during a 2-min walk test (2MWT).
Cognitive and behavioural factors
Coping style is measured with the Coping Inventory for
Stressful Situations (CISS-21) [81,82]. Three main cop-
ing styles can be distinguished: task-oriented coping,
emotion-oriented coping and avoidance coping. The
General Self Efficacy Scale will be used to assess opti-
mistic self-beliefs for coping with a variety of difficult life
demands [83]. Possible mood disorders will be assessedwith the Hospital Anxiety and Depression Scale (HADS)
[55]. The HADS consists of two subscales: depression
and anxiety. The tendency to fall asleep during daytime
is measured with the Epsworth Sleepiness Scale [84].
Perceptions of fatigue will be measured with the Brief
Illness Perception Questionnaire (B-FPQ), which as-
sesses cognitive and emotional representations of fatigue
[53]. The B-FPQ is an adaptation of the Brief Illness Per-
ception Questionnaire (B-IPQ), which measures illness
perceptions [85]. Fear of progression of MS is measured
with the Fear of disease Progression Questionnaire (FoP-Q)
[56,57]. Five factors are distinguished: affective reactions,
partnership/family, work, loss of autonomy and coping.
The Illness Cognitions Questionnaire (ICQ) measures
three different generic illness cognitions: helplessness,
acceptance and disease benefits [52]. The Social Support
List is used to measure the level of social interactions,
discrepancies and negative interactions [63].
Biological markers
An important part of the TREFAMS research
programme concerns the integration and longitudinal
study of clinical parameters and biological parameters
[38]. HPA-axis functioning will be assessed through the
collection and analysis of salivary cortisol. To determine
the Cortisol Awakening Response (CAR), saliva will be
collected immediately after awakening and after respect-
ively 30 min, 45 min and 60 min post-awakening. Fol-
lowing the fifth sample at 22:00 the participant takes 0.5
mg dexamethasone (low dose dexamethasone suppres-
sion test) and saliva is again collected the next morning,
immediately after awakening.
Blood will be drawn to determine levels and activity of
pro-and anti-inflammatory cytokines [39,86]. Blood and
saliva will be collected at the same fixed time-points as
for the other outcome measures.
Energy saving strategies
To assess which strategies the participants in all three RCTs
use to influence their fatigue, we developed the Fatigue
Strategies Questionnaire (FSQ). This questionnaire is based
on the Energy Conservation Strategies Survey (ECSS) [87]
to which we have added a number of strategies on physical
activity, cognition and behaviour. Participants will be asked
about the strategies they use and how effective these strat-
egies are. To facilitate the meta-analysis of ECM interven-
tions, the participants of the TREFAMS-ECM trial will fill
in the original ECSS at 16 weeks [87].
Sample size
Sample size was calculated based on the CIS20r subscale
fatigue. In order to detect a clinically relevant difference of
8 points on the CIS20r subscale fatigue between the study
groups in an MS population, with a SD of 12.7, a power of
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tients per group will be needed [47,88]. This amounts to
90 patients for each trial and 270 patients for the entire
TREFAMS-ACE programme. Sample size calculation was
not adjusted for longitudinal data analyses with repeated
measures [89], or for an eventual clustering by care pro-
viders or participating centres. Balancing these two fac-
tors, we expect that the power of our study will be >80%.
Randomisation
Patients eligible for participation in the study will be
randomised to either the trial-specific intervention or the
consultations with the MS-nurse after the baseline mea-
surements have been completed. The randomisation
scheme is computer-generated with random variable block
sizes. An independent investigator within each main study
centre will need to login to the web-based randomisation
facility to carry out the randomisation, and will inform the
patient and the therapist as to the therapy allocation.
Blinding
The assessors responsible for physical fitness tests and
interviewer-based measures will be told in which week
patients need to be measured but will not know which
treatment patients receive. Patients will be instructed
not to disclose which treatment they are receiving. Fur-
thermore, the analyses of blood and salivary in the clin-
ical chemistry laboratory, and the statistical analyses of
the between-group differences, will be performed by re-
search staff blinded to the treatment allocation of the
participants.
Serious adverse events
Based on previous research, AT, CBT, ECM and consulting
the MS-nurse are expected to be safe treatment methods in
patients with MS [16-21,23-26,90,91]. However, all thera-
pists and assessors involved in the studies will be instructed
to report all serious adverse events (SAE) to the principal
investigators, after which they will be reported to the Med-
ical Ethical Committee. An SAE is any untoward medical
occurrence in a participant that is not necessarily associated
with the treatment, but that is lethal, and/or threatens the
life of the participant, and/or requires hospitalisation or
prolongation of existing hospitalisation, and/or causes per-
sistent or significant disability or incapacity.
Treatment fidelity and compliance
Data regarding therapy compliance will be subtracted from
the administrative hospital databases and therapist notes.
Participants will receive an overview of all appointments
prior to the first session. If participants cancel or do not at-
tend a session, this session will be rescheduled within the
16-week time frame. Because therapy consists of 12
therapist-led sessions in 16 weeks, some rescheduling ispossible. Sessions will not be rescheduled if that means that
the 16-week time window will be extended by >1 week.
Statistical analyses of the RCTs and meta-analyses
The primary analyses of each separate RCT will be based
on the intention-to-treat principle using longitudinal data-
analysis techniques, such as Generalised Estimating Equa-
tions or Hierarchical Linear Mixed Models. To detect the
direct effects of the interventions, longitudinal models will
be constructed to analyse the differences between the inter-
vention groups regarding the course of within-group
changes during the 1-year follow-up period. Furthermore, a
meta-analysis of all TREFAMS-ACE data will be conducted
to investigate the relative effects of each treatment strategy.
In addition, statistical mediation analyses will be used to
examine the working mechanisms of the interventions re-
lated to, among others, changes in HPA-axis functioning
and changes in pro- and anti-inflammatory cytokine levels.
Discussion
The TREFAMS-ACE study will investigate the effective-
ness of three different non-invasive, non-pharmacological
rehabilitation treatment strategies aimed at reducing fa-
tigue and improving societal participation in patients with
MS. Furthermore, the mechanisms that underlie treat-
ment effects will be studied. This research programme
is expected to produce four related PhD-theses. By pub-
lication of the design, we wish to be fully transparent as
to the quality of the TREFAMS-ACE programme and
thus aim to avoid most of the methodological weak-
nesses reported in current Cochrane reviews in the field
of rehabilitation [92-95].
The TREFAMS-ACE study has a number of important
strengths, the first of which is a design including three
almost identical RCTs on the effectiveness of AT, CBT
and ECM, respectively. Our study may provide greater
insight into the exact pathophysiological mechanism(s)
behind MS-related fatigue and the pathways through
which AT, CBT and ECM exert their effect. Because the
same design and the same outcome measures are used,
at the end of the TREFAMS study an overall analysis can
be performed that allows factors to be controlled for that
might otherwise cause heterogeneity in a regular meta-
analysis of independent RCTs. This will enable a close
comparison of the treatment strategies within each trial
as well as a strong overall meta-analysis. Second, the
large cohort of fatigued MS patients that will be formed
will enable us to study the biological mechanisms that
explain fatigue and the mechanisms underlying the pos-
sible effectiveness of the treatment strategies. Recently,
Fischer et al. [38] formulated four criteria for biomarker
selection in clinical trials: the biomarker has to be linked
to the clinical outcome, that is, MS-related fatigue in
our study, and the biomarker should be modifiable in
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should be validly and reliably measured, and finally, the
duration of the clinical trial should be sufficiently long,
with an appropriate number of assessments, to allow the
biological and clinical outcome parameters to change.
All four criteria will be fulfilled by the TREFAMS-ACE
programme [86,96]. Third, due to the follow-up period
of 1 year, we will be able to investigate whether patients
implement the newly-learned skills in daily life and
whether the effect of therapy will be maintained over a
longer period of time. Fourth, the baseline data of the
three RCTs can be pooled, allowing several interesting
cross-sectional analyses. Fifth, there is valuable support
from the Dutch patient organisation, MSVN. The par-
ticipation of patient organisations in health research is
important when setting research agendas, during the de-
sign phase and during the study period, but it will also
enhance practical relevance during later dissemination
and implementation of study results [97]. Finally, a
strong network of academic rehabilitation departments
and MS centres will be formed, as the four study teams
work together closely. This will generate high quality
knowledge on the treatment of MS-related fatigue and
will also promote dissemination and sharing of expertise.
Some specific issues that apply to non-pharmacological
trials included in the TREFAMS-ACE programme need to
be discussed [28]. Regarding the blinding procedure,
everyone involved in an RCT should ideally be blinded but
this is not always feasible, as is often the case in RCTs
evaluating rehabilitation interventions [28,98,99]. Al-
though patients are not blinded and the two primary out-
come measures are both patient-reported, the assessment
of the physical fitness parameters, the analyses of blood
and salivary in the clinical chemistry laboratory and the
statistical analyses of the between-group differences will
all be performed by research staff blinded to the treatment
allocation of the participants.
With respect to the complexity of the interventions, we
decided to offer patients individual and mono-disciplinary
interventions, and no multidisciplinary group intervention
[100-102]. Two of the four active treatment intervention
programmes, that is, CBT and ECM, have long been avail-
able and further improved in recent years [30]. The AT
programme is largely based on the general principles of
exercise physiology [40]. The scientific underpinnings of
the valuable work of specialised MS-nurses is probably the
weakest aspect.
Contamination of treatment interventions is another
specific issue that might complicate the interpretation of
the study results. To avoid contamination via caregivers
in the same study centres, we designed three independ-
ent RCTs. Moreover, to avoid overlap between the CBT
and the ECM interventions, in the developmental phase
of the individual ECM protocol cognitive behaviouralaspects were further specified and should now totally
focus on managing energy. To prevent contamination
caused by participants, all participants are requested not
to start with co-interventions for fatigue during the
treatment period of the study. Because of the intensity of
the treatment, we expect that simultaneous interven-
tions aimed at reducing fatigue will probably only occur
in a small number of patients. Other co-interventions,
for example, disease modifying drugs, are monitored
throughout the study at every measurement.
Finally, the inclusion of participants may be slower
than anticipated. In theory, a large number of MS pa-
tients are fatigued but it may be difficult to awaken the
interest of every fatigued MS patient. To enhance par-
ticipation, we arranged a number of patient-friendly
measures, such as the setting-up of several study cen-
tres, travel allowance and the scheduling of appoint-
ments. In order to recruit a large group of MS patients,
we enlarged our network by involving regional patient
associations. In this respect, the support of and close
cooperation with the Dutch patient organisation Mul-
tiple Sclerosis Vereniging Nederland (MSVN) since the
design phase of the research programme has been very
important.
The TREFAMS-ACE study will provide insight into the
effectiveness of four mono-disciplinary rehabilitation treat-
ment methods for MS-related fatigue in individual patients.
The primary aim of these treatment methods is to reduce
fatigue and to improve societal participation. Furthermore,
to enhance our understanding of how these rehabilitation
interventions work, a study on biological outcome mea-
sures has been added. To improve current practice, tailored
and more focused rehabilitation programmes based on the
most effective treatment may represent - with a clearer pic-
ture of mechanisms of action - a first step in understanding
which types of patients may better respond to certain ther-
apies. Therefore, the TREFAMS-ACE results will also be
added to systematic reviews [29,30] and used to develop
and update clinical practice guidelines for the treatment of
MS-related fatigue [8,103].
Trials’ status
Patient recruitment commenced in October 2011. At the
time of manuscript submission 104 patients have been
randomised.
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